Completed Studies - Tuberculosis
- 1. Tools and Proven Active TB Case-Finding Interventions (2017-2018)
- 2. Enhanced TB Screening in Zambian Prisons (2010-2011)
- 3. A phase IIb, double-blind, randomised, placebo controlled study: M72/AS01E (2015-2019)
- 4. A Strategy Study of Immediate Versus Deferred Initiation of Antiretroviral Therapy
- 5. Reducing Early Mortality Among Patients with Advanced HIV Disease with empiric TB treatment (2011-2014)
- 6. Enhanced TB screening in ART Patients (2011-2012)
- 7. LAM Fresh- Frozen Equivalence Study (2018-2020)
- 8. The Tuberculosis Care Cascade in Lusaka, Zambia: patient experiences and preferences (2019-2020)
- 9. Integrating active tuberculosis case finding in antenatal services in Zambia (2011-2012)
- 10. A phase IIb, double-blind, randomised, placebo controlled study: M72/AS01E (2015-2019)
The purpose was to conduct systematic health facility and community-based case-finding interventions complemented by highly-sensitive screening and diagnostic tools to initiate a sustained increase in TB case detection in high-burden settings.
Sub Studies:https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0237931
Funder: Stop TB Partnership TB REACH (WHO) Project goal was to implement sustainable TB screening programs for 11,000 prisoners
Sub-studies
Funder: GSK/ AERAS
The aim of the study was to evaluate the efficacy (protective effect against active TB), safety and immunogenicity of GSK’s candidate vaccine M72/AS01E. The study was conducted between 2015 and 2018. A total of 3,573 HIV negative adults latently infected with TB but with no evidence of TB disease, aged between 18 – 50, were included in this study and were followed up for 3 years.
PI: Stewart Reid
Funder: ACTG ( DAIDs)
Phase IV, randomized, open-label study among HIV + adults with confirmed or presumed TB. Patients were randomized to immediate ART (<2 weeks of initiating TB treatment) or early ART ( 8-12 weeks after initiating TB treatment).The main study endpoint was all cause mortality and new AIDs defining illness by 48 weeks.(2006-2010)
Funder: ACTG (NIH)
The study goal was to assess whether empirical tuberculosis treatment would reduce early mortality compared with isoniazid preventive therapy in high-burden settings.
Funder: US Centers for Disease Control and Prevention
Project objectives
The primary purpose of this proposal was to address the gaps in knowledge related to the experiences of newly diagnosed TB patients, especially people living with HIV (PLHIV) and men, as well as to better understand patient preferences for different interventions that may help to overcome individual and systems-level barriers to health-seeking and TB diagnosis.
The study was conducted in 3 out-patient antenatal care (ANC) clinics in Lusaka, Zambia.
The study objective was to estimate tuberculosis (TB) prevalence in human immunodeficiency virus (HIV) infected and symptomatic, non-HIV-infected pregnant women and explore the feasibility of routine TB screening in ANC settings.
Peer educators administered TB symptom questionnaires to pregnant women attending their first ANC clinic visit. Presumptive TB patients were defined as all HIV-infected women and symptomatic non-HIV-infected women. Sputum samples were tested using smear microscopy and culture to estimate TB prevalence.Integrating active tuberculosis case finding in antenatal services in Zambia. Kancheya N, Luhanga D, Harris JB, Morse J, Kapata N, Bweupe M, Henostroza G, Reid SE.Int J Tuberc Lung Dis. 2014 Dec;18(12):1466-72. doi: 10.5588/ijtld.14.0920.
The aim of the study was to evaluate the efficacy (protective effect against active TB), safety and immunogenicity of GSK’s candidate vaccine M72/AS01E. The study was conducted between 2015 and 2018. A total of 3,573 HIV negative adults latently infected with TB but with no evidence of TB disease, aged between 18 – 50, were included in this study and were followed up for 3 years. Findings. The vaccine was found to reduce the risk of developing TB by 50% and was also determined to be safe and well tolerated
